Thirty million doses of the new German crown vaccine, Taiwan failed to make the Chinese media angry: bragging

Toyo from Taiwan acquired the new German corona vaccine BioNTech (BNT) and announced the breakdown. Toyo said on the 3rd that because BNT and the government were having difficulty reaching a consensus on the quantity and price, they could not manage the import of the vaccine as scheduled. However, Zhuang Renxiang, a spokesman for the Epidemic Command Center, said the reasons for the barrier. Because Toyo was unable to provide authorization documents and formal contracts, the negotiations could not continue. In this regard, Kuomintang lawmakers questioned Dongyang’s use of inside information for the shares. The Chinese media “Global Times” published an article on the 4th day of the “presumptuous” DPP government, but in the end they got nothing.

Toyo Pharmaceuticals of Taiwan previously obtained “conditional authorization” for the sale of the new crown vaccine from BNT in Taiwan. However, it announced on day 3 that it could not import the vaccine successfully due to lack of agreement with the government in terms of quantity and price. However, Zhuang Renxiang stated that it was because he obtained “direct authorization” from BNT that negotiations were not possible.

Toyo responded again on the night of the 3rd. During the ongoing negotiation with the government, although it actively sought to extend the BNT’s authorization period, it was unable to continue providing valid supporting documents due to non-compliance with some business conditions.

In response to this, the “Global Times” titled “After bragging, 30 million doses of the new German crown vaccine, Taiwan failed to …”, the author mocked the DPP for “boasting,” but at end broke the situation and even called “the island People are quite concerned.” If vaccines cannot be obtained in the first quarter of next year, and other regions continue to open and unblock them, Taiwan will still have to prevent high-level epidemics, which will have an unprecedented impact on the economy.

However, in China, most national authorities are concerned about whether the matter involves stock trading and insider trading.

Kuomintang lawmaker Lai Shibao noted that an important message will be released on that day and that the volume of transactions will skyrocket in the morning, likely to violate the law on insider trading and market speculation, and it specifically requires that the Financial Management Committee and inspections intervene in the investigation. Netizens also said, “Obviously, it’s about stock trading,” “I don’t think so if there’s no insider information,” “It’s a scam at all” and “Retail investors are so sorry!”

Toyo from Taiwan acquired the new German corona vaccine BioNTech (BNT) and announced the breakdown. Toyo said on the 3rd that because BNT and the government were having difficulty reaching a consensus on the quantity and price, they could not manage the import of the vaccine as scheduled. However, Zhuang Renxiang, a spokesman for the Epidemic Command Center, said the reasons for the barrier. Because Toyo was unable to provide authorization documents and official contracts, the negotiations could not continue.

In response, Kuomintang lawmakers questioned Dongyang’s use of inside information and stocks, while the Chinese “Global Times” media arrogantly acidified the DPP into “bragging” but ultimately got nothing.